Accelerating the pace of drug discovery

Paraza Pharma, Inc. is an innovative company with an aim to significantly improve the efficiency of the drug discovery process. Our experienced drug discovery team will help you design, define, execute, and meet your program milestones from lead identification through lead optimization and development candidate selection.

Learn more
“You have assembled a truly remarkable team who not only knows how to present science but also knows the science of drug discovery in depth”
Client Testimonial


Arshad Siddiqui, Ph.D.
Founder and CEO

Dr. Siddiqui received a Ph.D. degree in chemistry from the University of Waterloo, Ontario, Canada. He has over twenty-five years of experience in biotechnology and pharmaceutical companies including Shire-BioChem Pharma (Montreal, Canada), Neogenesis Pharmaceuticals (Cambridge, MA), Schering-Plough (Cambridge, MA) and Merck (Cambridge, MA). Dr. Siddiqui is a co-recipient of the Prix-Galien (Canada, 1996), Prix Genesis (Canada, 2013) and University of Waterloo Distinguished Alumni Award (2015).

Jean-Marc Lachance, CA, CPA, MBA
Finance Director

Mr. Lachance is a member of the Chartered Professionnal Accountants and has a MBA (finance) from Hautes Études Commerciales, University of Montreal. Mr. Lachance gained more than 15 years of experience in senior finance position in health and biotechnology sector, including CFO and Vice President roles in public and private companies.

Danièle DesChênes, LLB, MBA
Chief Legal Council

Ms. Danièle DesChênes is a business and intellectual property lawyer with more than 25 years of experience as a legal counsel for companies in the life sciences industry. Ms. DesChênes has a law degree from the University of Montreal, a MBA (finance) from Hautes études Commerciales, University of Montreal, a Certificate on European business law and issues dealing with market access.

Scientific Advisory Board

William (Bill) J. Greenlee, Ph.D.

Dr. Greenlee received his Ph.D. degree from Harvard University with Professor Robert Woodward. Dr. Greenlee has worked at Merck Research Laboratories, Rahway, NJ, and at the Schering-Plough Research Institute, Kenilworth, NJ, Dr. Greenlee has been in senior leadership positions in these companies heading up large medicinal chemistry groups. His career spans over 35 years, and includes contributions to the discovery of enalapril (Vasotec™) and lisinopril (Prinivil™), as well as other drug candidates that are currently in clinical trials. Dr. Greenlee has been the recipient of numerous honors and awards including the Alfred Burger Award in Medicinal Chemistry from the American Chemical Society (ACS) in 2004. He was inducted into the ACS Medicinal Chemistry Hall of Fame in 2006 and was elected a Fellow of the ACS in 2009. Dr. Greenlee is also a Perspectives Editor for the Journal of Medicinal Chemistry, and serves on the Editorial Advisory Board for ACS Medicinal Chemistry Letters. Dr. Greenlee is co-author of over 200 research papers, and an inventor of over 70 issued U.S. patents.

Timothy F. Jamison, Ph.D.

Dr. Jamison, Full Professor in the Department of Chemistry of the Massachusetts Institute of Technology (MIT), received his Bachelor’s degree from the University of California, Berkeley, and Ph.D. from Harvard University. Professor Jamison has received numerous honors and awards in recognition of his research contributions, including the Royal Society of Chemistry Merck Award, American Chemical Society Cope Scholar Award, Sloan Research Fellowship, GlaxoSmithKline Scholar Award, Amgen Young Investigator Award, Boehringer Ingelheim New Investigator Award, National Science Foundation CAREER Award, 3M Innovation Award. Professor Jamison’s research program focuses on the development of new methods and continuous flow technologies for the synthesis of organic molecules. Professor Jamison has published over 100 research articles and 15 patents.

Peter Winocour, Ph.D.

Dr. Winocour has over 12 years in academia and 15 years of in-depth multidisciplinary experience in the pharmaceutical industry in areas of discovery and preclinical development of small molecule drugs, including pharmacokinetics, toxicology, efficacy models, project management and preparation and submission of IND/CTA/IMPD packages to regulatory authorities. He was Head of the Pharmacology and Toxicology Department at Shire-Biochem Pharma and Director of Preclinical Development at Aegera Therapeutics. Previously, Dr. Winocour was an Associate Professor in the Department of Pathology at McMaster University and an Adjunct Professor in the Department of Pathology at McGill University. Dr. Winocour holds a Ph.D. from the University of Southampton, UK, and has published over 76 research papers and has 34 invited lectures.

Partner with us!

Whether working as fully integrated members of your drug discovery team or providing expertise to solve specific problems, our world-class Drug Discovery Experts can help you reach your project goals.

Faces of Paraza

We're Currently Hiring!

Paraza Pharma, Inc. is a rapidly growing drug discovery research organization which offers a dynamic and collaborative work environment where scientific excellence, innovation and creativity are at the forefront.